Trial · NCT07909850
Development and Validation of a TIPS Prognostic Model
NCT07909850, Not yet recruiting, The Second Affiliated Hospital of Chongqing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Development and Validation of a TIPS Prognostic Model. Trials, record NCT07909850. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909850
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Development and Validation of a TIPS Prognostic Model
- NCT number
- NCT07909850
- Status
- Not yet recruiting
- Enrollment
- 1,490 participants, estimated
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical University
- Conditions
- Portal Hypertension Related to Cirrhosis, Ascites, Esophageal Variceal Bleeding
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TIPS stent dysfunction within 1 year after TIPS | Within 1 year after the TIPS procedure (from the index TIPS procedure through 12 months). | Incidence of TIPS stent dysfunction, defined as either: (1) no clinical response or recurrence of portal hypertension complications (ascites not relieved or new/worsening ascites; variceal rebleeding; new or unexplained hepatic hydrothorax); or (2) Doppler ultrasound evidence of TIPS stent dysfunction (e.g., significantly abnormal intra-stent flow velocity, decreased main portal vein velocity, or hepatofugal flow in intrahepatic portal branches). Either condition must be confirmed by subsequent angiography showing stent or outflow tract stenosis ≥50% or complete occlusion, or by a portal pressure gradient (PPG) \>12 mmHg or a ≤50% reduction from the preprocedural baseline PPG. |
| Secondary | Further decompensation within 3 years after TIPS | Within 3 years after the TIPS procedure. | Incidence of further decompensation, defined per Baveno VII as any of the following: (1) a second portal hypertension-related decompensating event (ascites, variceal bleeding, or hepatic encephalopathy); (2) recurrent variceal bleeding, recurrent ascites (requiring ≥3 large-volume paracenteses within 1 year), recurrent encephalopathy, spontaneous bacterial peritonitis, and/or hepatorenal syndrome-related acute kidney injury; or (3) new-onset ascites or encephalopathy after TIPS in patients whose only pre-TIPS decompensation was variceal bleeding |
| Secondary | Recompensation within 3 years after TIPS | Within 3 years after the TIPS procedure. | Incidence of recompensation, defined per Baveno VII as sustained resolution of ascites, hepatic encephalopathy, and variceal bleeding for at least 12 months after removal/control of the underlying etiology, together with stable improvement in liver function. |
| Secondary | Liver failure within 1 year after TIPS | Within 1 year after the TIPS procedure. | Incidence of liver failure, defined per the EASL Clinical Practice Guidelines on acute-on-chronic liver failure (2023) as total bilirubin ≥12 mg/dL plus any of the following: (1) INR ≥2.5; (2) serum creatinine ≥2.0 mg/dL or need for renal replacement therapy; (3) hepatic encephalopathy grade ≥3 (West Haven); (4) need for vasopressors to maintain blood pressure; or (5) PaO2/FiO2 ≤200 or SpO2/FiO2 ≤214. |
| Secondary | Liver failure within 3 years after TIPS | Within 3 years after the TIPS procedure. | Incidence of liver failure, defined per the EASL Clinical Practice Guidelines on acute-on-chronic liver failure (2023) as total bilirubin ≥12 mg/dL plus any of the following: (1) INR ≥2.5; (2) serum creatinine ≥2.0 mg/dL or need for renal replacement therapy; (3) hepatic encephalopathy grade ≥3 (West Haven); (4) need for vasopressors to maintain blood pressure; or (5) PaO2/FiO2 ≤200 or SpO2/FiO2 ≤214. |
| Secondary | Liver disease-related death within 3 years after TIPS | Within 3 years after the TIPS procedure. | Incidence of death directly attributable to liver disease, including death from liver failure, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, or other liver-related causes, as recorded during routine follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909850
GET https://conductscience.org/api/trials/v1/NCT07909850/registered